Stocks Health care COLL
NASDAQ · Health careCollegium Pharmaceutical, Inc (COLL)
Collegium Pharmaceutical, Inc brought in $808.2M of revenue over the twelve months to June 30, 2026, up 14.3% from a year earlier. Net income was $47.9M, a net margin of 5.9%. Operating cash flow minus capital spending left $327.6M of free cash flow in fiscal 2025. At June 30, 2026 it held $129.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Collegium Pharmaceutical, Inc does
Collegium Pharmaceutical, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COLL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $780.6M | $62.9M | $1.73 | $327.6M |
| 2024 | $631.4M | $69.2M | $1.86 | $203.3M |
| 2023 | $566.8M | $48.2M | $1.29 | $274.3M |
| 2022 | $463.9M | -$25M | -$0.74 | $122.6M |
| 2021 | $276.9M | $71.5M | $1.86 | $101.6M |
| 2020 | $310M | $26.8M | $0.76 | $88.4M |
Where COLL ranks in Health care
Latest SEC filings
What Collegium Pharmaceutical, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 24, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- August 5, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- June 30, 2026Exhibits 8-K/A
- June 1, 2026
- June 1, 2026
What is COLL worth? A DCF from its reported cash flow
Insider trades
What the people running Collegium Pharmaceutical, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about COLL
What does Collegium Pharmaceutical, Inc do?
Collegium Pharmaceutical, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COLL.
Is Collegium Pharmaceutical, Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $47.9M on revenue of $808.2M, a net margin of 5.9%.
How much revenue does Collegium Pharmaceutical, Inc make?
Over the twelve months to June 30, 2026 Collegium Pharmaceutical, Inc reported revenue of $808.2M. That is 14.3% more than a year earlier.
When did Collegium Pharmaceutical, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 24, 2026.
Similar companies
Compare COLL with
Follow COLL
Get an email when Collegium Pharmaceutical, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow COLL: get an email when it filesWhere the numbers come from
Financial figures are the values Collegium Pharmaceutical, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.